Lyell announces two oral presentations from the phase 1/2 clinical trial of ronde-cel for the treatment of aggressive large b-cell lymphoma at the 67th ash annual meeting and exposition

South san francisco, calif., nov. 03, 2025 (globe newswire) -- lyell immunopharma, inc. (nasdaq: lyel), a late-stage clinical company advancing a pipeline of next-generation car t-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational data from the phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel, also known as lyl314) for the treatment of aggressive large b-cell lymphoma (lbcl) will be presented at the 67th american society of hematology (ash) annual meeting and exposition.
ASH Ratings Summary
ASH Quant Ranking